Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia

Lindsay M. Avery, Joseph L. Kuti, Maja Weisser, Adrian Egli, Michael J. Rybak, Evan J. Zasowski, Cesar A. Arias, German A. Contreras, Pearlie Pao Ee Chong, Samuel L. Aitken, Adam J. DiPippo, Jann Tay Wang, Nicholas S. Britt, David P. Nicolau

Research output: Contribution to journalArticle

Abstract

Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia. Whilst a free drug area under the concentration–time curve to minimum inhibitory concentration (fAUC/MIC) ratio >27.4 is associated with 30-day survival with daptomycin monotherapy, it is unknown whether receipt of other antibiotics affects this threshold. Data were pooled from seven published trials assessing outcomes in daptomycin-treated enterococcal bacteraemia, including patients receiving daptomycin (≥72 h) and any β-lactam, intravenous aminoglycoside, linezolid, tigecycline and/or vancomycin. Exposures were calculated using a published population pharmacokinetic model based on creatinine clearance, 90% protein binding and daptomycin Etest MIC. The fAUC/MIC threshold predictive of 30-day survival was determined by classification and regression tree analysis. Following pooling of data, 240 adults were included; 137 (57.1%) were alive at 30 days. A majority of patients were immunosuppressed (65.8%) and received a β-lactam (94.6%). Examining the threshold in low-acuity patients (n = 135) to control for co-morbidities, these patients were more likely to survive when fAUC/MIC >12.3 was achieved (63.2% vs. 20.0%; P = 0.015). The difference remained significant in a multivariable logistic regression model that controlled for infection source and immunosuppression (P = 0.017). This threshold is 2-fold lower than that observed with daptomycin monotherapy. Probabilities of threshold attainment using a 10 mg/kg/day dose were 100% for isolates with MICs ≤ 2 mg/L and 95.2% for a 12 mg/kg/day dose for MICs of 4 mg/L. These data support the use of high-dose daptomycin in combination with another antibiotic for treatment of enterococcal bacteraemia.

Original languageEnglish (US)
Pages (from-to)346-350
Number of pages5
JournalInternational Journal of Antimicrobial Agents
Volume54
Issue number3
DOIs
StatePublished - Sep 1 2019

Fingerprint

Daptomycin
Bacteremia
Anti-Bacterial Agents
Microbial Sensitivity Tests
Area Under Curve
Lactams
Linezolid
Therapeutics
Disk Diffusion Antimicrobial Tests
Logistic Models
Pharmaceutical Preparations
Patient Acuity
Survival
Aminoglycosides
Vancomycin
Protein Binding
Immunosuppression
Meta-Analysis
Creatinine
Pharmacokinetics

Keywords

  • Bacteraemia
  • Combination therapy
  • Daptomycin
  • Enterococcus
  • Pharmacodynamics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. / Avery, Lindsay M.; Kuti, Joseph L.; Weisser, Maja; Egli, Adrian; Rybak, Michael J.; Zasowski, Evan J.; Arias, Cesar A.; Contreras, German A.; Chong, Pearlie Pao Ee; Aitken, Samuel L.; DiPippo, Adam J.; Wang, Jann Tay; Britt, Nicholas S.; Nicolau, David P.

In: International Journal of Antimicrobial Agents, Vol. 54, No. 3, 01.09.2019, p. 346-350.

Research output: Contribution to journalArticle

Avery, LM, Kuti, JL, Weisser, M, Egli, A, Rybak, MJ, Zasowski, EJ, Arias, CA, Contreras, GA, Chong, PPE, Aitken, SL, DiPippo, AJ, Wang, JT, Britt, NS & Nicolau, DP 2019, 'Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia', International Journal of Antimicrobial Agents, vol. 54, no. 3, pp. 346-350. https://doi.org/10.1016/j.ijantimicag.2019.07.002
Avery, Lindsay M. ; Kuti, Joseph L. ; Weisser, Maja ; Egli, Adrian ; Rybak, Michael J. ; Zasowski, Evan J. ; Arias, Cesar A. ; Contreras, German A. ; Chong, Pearlie Pao Ee ; Aitken, Samuel L. ; DiPippo, Adam J. ; Wang, Jann Tay ; Britt, Nicholas S. ; Nicolau, David P. / Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. In: International Journal of Antimicrobial Agents. 2019 ; Vol. 54, No. 3. pp. 346-350.
@article{40d2c22d71ec467ba1ab954647d6fac7,
title = "Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia",
abstract = "Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia. Whilst a free drug area under the concentration–time curve to minimum inhibitory concentration (fAUC/MIC) ratio >27.4 is associated with 30-day survival with daptomycin monotherapy, it is unknown whether receipt of other antibiotics affects this threshold. Data were pooled from seven published trials assessing outcomes in daptomycin-treated enterococcal bacteraemia, including patients receiving daptomycin (≥72 h) and any β-lactam, intravenous aminoglycoside, linezolid, tigecycline and/or vancomycin. Exposures were calculated using a published population pharmacokinetic model based on creatinine clearance, 90{\%} protein binding and daptomycin Etest MIC. The fAUC/MIC threshold predictive of 30-day survival was determined by classification and regression tree analysis. Following pooling of data, 240 adults were included; 137 (57.1{\%}) were alive at 30 days. A majority of patients were immunosuppressed (65.8{\%}) and received a β-lactam (94.6{\%}). Examining the threshold in low-acuity patients (n = 135) to control for co-morbidities, these patients were more likely to survive when fAUC/MIC >12.3 was achieved (63.2{\%} vs. 20.0{\%}; P = 0.015). The difference remained significant in a multivariable logistic regression model that controlled for infection source and immunosuppression (P = 0.017). This threshold is 2-fold lower than that observed with daptomycin monotherapy. Probabilities of threshold attainment using a 10 mg/kg/day dose were 100{\%} for isolates with MICs ≤ 2 mg/L and 95.2{\%} for a 12 mg/kg/day dose for MICs of 4 mg/L. These data support the use of high-dose daptomycin in combination with another antibiotic for treatment of enterococcal bacteraemia.",
keywords = "Bacteraemia, Combination therapy, Daptomycin, Enterococcus, Pharmacodynamics",
author = "Avery, {Lindsay M.} and Kuti, {Joseph L.} and Maja Weisser and Adrian Egli and Rybak, {Michael J.} and Zasowski, {Evan J.} and Arias, {Cesar A.} and Contreras, {German A.} and Chong, {Pearlie Pao Ee} and Aitken, {Samuel L.} and DiPippo, {Adam J.} and Wang, {Jann Tay} and Britt, {Nicholas S.} and Nicolau, {David P.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.ijantimicag.2019.07.002",
language = "English (US)",
volume = "54",
pages = "346--350",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia

AU - Avery, Lindsay M.

AU - Kuti, Joseph L.

AU - Weisser, Maja

AU - Egli, Adrian

AU - Rybak, Michael J.

AU - Zasowski, Evan J.

AU - Arias, Cesar A.

AU - Contreras, German A.

AU - Chong, Pearlie Pao Ee

AU - Aitken, Samuel L.

AU - DiPippo, Adam J.

AU - Wang, Jann Tay

AU - Britt, Nicholas S.

AU - Nicolau, David P.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia. Whilst a free drug area under the concentration–time curve to minimum inhibitory concentration (fAUC/MIC) ratio >27.4 is associated with 30-day survival with daptomycin monotherapy, it is unknown whether receipt of other antibiotics affects this threshold. Data were pooled from seven published trials assessing outcomes in daptomycin-treated enterococcal bacteraemia, including patients receiving daptomycin (≥72 h) and any β-lactam, intravenous aminoglycoside, linezolid, tigecycline and/or vancomycin. Exposures were calculated using a published population pharmacokinetic model based on creatinine clearance, 90% protein binding and daptomycin Etest MIC. The fAUC/MIC threshold predictive of 30-day survival was determined by classification and regression tree analysis. Following pooling of data, 240 adults were included; 137 (57.1%) were alive at 30 days. A majority of patients were immunosuppressed (65.8%) and received a β-lactam (94.6%). Examining the threshold in low-acuity patients (n = 135) to control for co-morbidities, these patients were more likely to survive when fAUC/MIC >12.3 was achieved (63.2% vs. 20.0%; P = 0.015). The difference remained significant in a multivariable logistic regression model that controlled for infection source and immunosuppression (P = 0.017). This threshold is 2-fold lower than that observed with daptomycin monotherapy. Probabilities of threshold attainment using a 10 mg/kg/day dose were 100% for isolates with MICs ≤ 2 mg/L and 95.2% for a 12 mg/kg/day dose for MICs of 4 mg/L. These data support the use of high-dose daptomycin in combination with another antibiotic for treatment of enterococcal bacteraemia.

AB - Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia. Whilst a free drug area under the concentration–time curve to minimum inhibitory concentration (fAUC/MIC) ratio >27.4 is associated with 30-day survival with daptomycin monotherapy, it is unknown whether receipt of other antibiotics affects this threshold. Data were pooled from seven published trials assessing outcomes in daptomycin-treated enterococcal bacteraemia, including patients receiving daptomycin (≥72 h) and any β-lactam, intravenous aminoglycoside, linezolid, tigecycline and/or vancomycin. Exposures were calculated using a published population pharmacokinetic model based on creatinine clearance, 90% protein binding and daptomycin Etest MIC. The fAUC/MIC threshold predictive of 30-day survival was determined by classification and regression tree analysis. Following pooling of data, 240 adults were included; 137 (57.1%) were alive at 30 days. A majority of patients were immunosuppressed (65.8%) and received a β-lactam (94.6%). Examining the threshold in low-acuity patients (n = 135) to control for co-morbidities, these patients were more likely to survive when fAUC/MIC >12.3 was achieved (63.2% vs. 20.0%; P = 0.015). The difference remained significant in a multivariable logistic regression model that controlled for infection source and immunosuppression (P = 0.017). This threshold is 2-fold lower than that observed with daptomycin monotherapy. Probabilities of threshold attainment using a 10 mg/kg/day dose were 100% for isolates with MICs ≤ 2 mg/L and 95.2% for a 12 mg/kg/day dose for MICs of 4 mg/L. These data support the use of high-dose daptomycin in combination with another antibiotic for treatment of enterococcal bacteraemia.

KW - Bacteraemia

KW - Combination therapy

KW - Daptomycin

KW - Enterococcus

KW - Pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=85070560107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070560107&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2019.07.002

DO - 10.1016/j.ijantimicag.2019.07.002

M3 - Article

C2 - 31284042

AN - SCOPUS:85070560107

VL - 54

SP - 346

EP - 350

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 3

ER -